TABLE 1

Single- and Dual-Time-Point Imaging SUVs in Patients with Malignant Lesions

Sample	Average SUV at time:			% Change in average SUV	Histopathologic findings	Tumor grade	Size (cm)
Sample		1	2	% Change in average SUV	Histopathologic findings	Tumor grade	Size (cm)
1	1.2	1.4	16.7	IDC	Low	0.2
2	1.5	1.7	13.3	IDC	High	1.5
3	0.7	0.7	0	IDC + ILC	Moderate	3.5
4	0.6	0.7	16.7	IDC	Not known	1.0
5	1.1	0.9	−18.2	IDC	Moderate	0.2
6	3.0	3.3	10.0	IDC	High	2.0
7	2.1	2.3	9.5	IDC	Moderate	2.4
8	2.1	2.2	4.8	IDC + ILC	Low	4.0
9	1.4	1.6	14.3	IDC	Moderate	0.5
10	1.9	2.3	21.1	IDC	High	Not known
11	1.8	1.9	5.6	ILC + IDC	Moderate	1.5
12	0.8	0.9	12.5	IDC	Low	Not known
13	7.4	9.1	23.0	IDC	High	Not known
14	2.3	2.5	8.7	IDC	Moderate	2.9
15	1.8	2.0	11.1	IDC	Moderate	1.9
16	0.9	0.9	0	IDC	Moderate	1.6
17	2.0	2.3	15.0	IDC	Low	3.5
18	2.7	3.5	29.6	IDC + ILC	High	2.4
19	0.6	0.8	33.3	IDC	Low	1.6
20	11.7	15.7	34.2	IDC	High	2.6
21	0.7	0.8	14.3	IDC	Low	1.4
22	2.9	3.2	10.3	IDC	Moderate	2.1
23	15.3	20.0	30.7	IDC	High	2.8
24	5.7	5.9	3.5	IDC	High	1.9
25	0.7	0.7	0	IDC + ILC	Low	0.3
26	6.0	6.9	15.0	Medullary carcinoma	High	1.8
27	5.2	5.8	11.5	IDC	Moderate	2.5
28	2.2	2.4	9.1	IDC	High	2.2
29	1.5	1.7	13.3	IDC	Moderate	1.2
30	0.4	0.4	0	IDC	Moderate	0.4
31	2.5	2.6	4.0	IDC	High	0.5
32	2.5	2.7	8.0	IDC	Low	Not known
33	1.7	1.9	11.8	IDC + ILC	Low	Not known
34	1.4	1.7	21.4	IDC	Moderate	0.9
35	0.8	1.0	25	IDC	High	Not known
36	2.7	3.6	33.3	IDC	Moderate	1.0
37	6.2	7.7	24.2	IDC	Moderate	4.0
38	3.0	3.2	6.7	IDC	Moderate	Not known
39	3.3	3.0	−9.1	Adenocarcinoma	Not known	Not known
Mean	2.88	3.38	12.7
SD	3.04	3.98	11.4